Bickerstaff brainstem encephalitis and Fisher syndrome: Anti-GQ1b antibody syndrome

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 84, Issue 5, 2013, Pages 576-583

  Shahrizaila, Nortina ^a   Yuki, Nobuhiro ^b  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

GANGLIOSIDE GQ 1B; GANGLIOSIDE GQ 1B ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; METHYLPREDNISOLONE; PREDNISOLONE;

ACUTE MOTOR AXONAL NEUROPATHY; ANTIBODY PRODUCTION; AREFLEXIA; ATAXIA; BICKERSTAFF BRAINSTEM ENCEPHALITIS; CAMPYLOBACTER ENTERITIS; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; COMPARATIVE STUDY; CONSCIOUSNESS DISORDER; DEMYELINATING NEUROPATHY; DIFFERENTIAL DIAGNOSIS; ENCEPHALITIS; GQ1B ANTIBODY SYNDROME; GUILLAIN BARRE SYNDROME; HUMAN; HYPERREFLEXIA; IMMUNOPATHOLOGY; MEDICAL HISTORY; MOLECULAR DYNAMICS; MOLECULAR MIMICRY; NEUROPATHOLOGY; NONHUMAN; OPHTHALMOPLEGIA; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PHARYNGEAL CERVICAL BRACHIAL WEAKNESS; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; REVIEW; WEAKNESS;

EID: 84876132908     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2012-302824     Document Type: Review

References (73)

1. Bickerstaff ER, Cloake PC. Mesencephalitis and rhombencephalitis. Br Med J 1951;2:77-81.
2. Bickerstaff ER. Brain-stem encephalitis: further observations on a grave syndrome with benign prognosis. Br Med J 1957;1:1384-7.
3. Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med 1956;255:57-65.
4. Chiba A, Kusunoki S, Shimizu T, et al. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol 1992;31:677-9.
5. Yuki N, Sato S, Tsuji S, et al. An immunologic abnormality common to Bickerstaff's brain stem encephalitis and Fisher's syndrome. J Neurol Sci 1993;118:83-7. (Pubitemid 23269971)
6. Yuki N. Fisher syndrome and Bickerstaff brainstem encephalitis (Fisher-Bickerstaff syndrome). J Neuroimmunol 2009;215:1-9.
7. Odaka M, Yuki N, Hirata K. Anti-GQ1b IgG antibody syndrome: clinical and immunological range. J Neurol Neurosurg Psychiatry 2001;70:50-5. (Pubitemid 32096120)
8. Munsat TL, Barnes JE. Relation of multiple cranial nerve dysfunction to the Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1965;28:115-20.
9. Guillain G. Les polyradiculonévrites avec dissociation alumbinocytologique et á evolution favorable. (Syndrome de Guillain et Barré.). J Belge Neurol Psychiat 1938;38:323-9.
10. Al-Din AN, Anderson M, Bickerstaff ER, et al. Brainstem encephalitis and the syndrome of Miller Fisher: a clinical study. Brain 1982;105:481-95. (Pubitemid 12004279)
11. Meienberg O, Ryffel E. Supranuclear eye movement disorders in Fisher's syndrome of ophthalmoplegia, ataxia, and areflexia: report of a case and literature review. Arch Neurol 1983;40:402-5. (Pubitemid 13060498)
12. Ropper AH. The CNS in Guillain-Barré syndrome. Arch Neurol 1983;40:397-8.
13. Anderson M, Al-din AN, Bickerstaff ER, et al. The CNS in Guillain-Barré syndrome. Arch Neurol 1984;41:705.
14. Odaka M, Yuki N, Yamada M, et al. Bickerstaff's brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barré syndrome. Brain 2003;126:2279-90. (Pubitemid 37432371)
15. Ito M, Kuwabara S, Odaka M, et al. Bickerstaff's brainstem encephalitis and Fisher syndrome form a continuous spectrum: clinical analysis of 581 cases. J Neurol 2008;255:674-82.
16. Sejvar JJ, Baughman AL, Wise M, et al. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology 2011;36:123-33.
17. Ropper AH, Wijdicks EFM, Truax BT. Guillain-Barré Syndrome: F. A. Davis. FA Davis, Philadelphia, 1991.
18. Bogliun G, Beghi E. Incidence and clinical features of acute inflammatory polyradiculoneuropathy in Lombardy, Italy, 1996. Acta Neurol Scand 2004;110:100-6. (Pubitemid 39044046)
19. Lyu RK, Tang LM, Cheng SY, et al. Guillain-Barré syndrome in Taiwan: a clinical study of 167 patients. J Neurol Neurosurg Psychiatry 1997;63:494-500.
20. Mori M, Kuwabara S, Fukutake T, et al. Clinical features and prognosis of Miller Fisher syndrome. Neurology 2001;56:1104-6. (Pubitemid 32336323)
21. Chiba A, Kusunoki S, Obata H, et al. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology 1993;43:1911-17. (Pubitemid 23318855)
22. Yuki N. Acute paresis of extraocular muscles associated with IgG anti-GQ1b antibody. Ann Neurol 1996;39:668-72.
23. Ropper AH. Further regional variants of acute immune polyneuropathy: bifacial weakness or sixth nerve paresis with paresthesias, lumbar polyradiculopathy, and ataxia with pharyngeal-cervical-brachial weakness. Arch Neurol 1994;51:671-5. (Pubitemid 24201885)
24. Susuki K, Yuki N, Muramatsu M, et al. Unilateral ophthalmoparesis and limb ataxia associated with anti-GQ1b IgG antibody. J Neurol 2000;247:652-3.
25. Ichikawa H, Kamiya Y, Susuki K, et al. Unilateral oculomotor nerve palsy associated with anti-GQ1b IgG antibody. Neurology 2002;59:957-8.
26. Tatsumoto M, Odaka M, Hirata K, et al. Isolated abducens nerve palsy as a regional variant of Guillain-Barré syndrome. J Neurol Sci 2006;243:35-8.
27. Richter RB. The ataxic form of polyradiculoneuritis (Landry-Guillain- Barré syndrome): clinical and pathologic observations. J Neuropathol Exp Neurol 1962;21:171-84.
28. Kusunoki S, Chiba A, Kanazawa I. Anti-GQ1b IgG antibody is associated with ataxia as well as ophthalmoplegia. Muscle Nerve 1999;22:1071-4. (Pubitemid 29360252)
29. Yuki N, Susuki K, Hirata K. Ataxic Guillain-Barré syndrome with anti-GQ1b antibody: relation to Miller Fisher syndrome. Neurology 2000;54:1851-3. (Pubitemid 30428417)
30. Ito M, Matsuno K, Sakumoto Y, et al. Ataxic Guillain-Barré syndrome and acute sensory ataxic neuropathy form a continuous spectrum. J Neurol Neurosurg Psychiatry 2011;82:294-9.
31. Radziwill AJ, Steck AJ, Borruat FX, et al. Isolated internal ophthalmoplegia associated with IgG anti-GQ1b antibody. Neurology 1998;50:307. (Pubitemid 28106066)
32. Yuki N, Koga M, Hirata K. Isolated internal ophthalmoplegia associated with immunoglobulin G anti-GQ1b antibody. Neurology 1998;51:1515-16. (Pubitemid 28520606)
33. O'Leary CP, Veitch J, Durward WF, et al. Acute oropharyngeal palsy is associated with antibodies to GQ1b and GT1a gangliosides. J Neurol Neurosurg Psychiatry 1996;61:649-51. (Pubitemid 27023349)
34. Onodera M, Mori M, Koga M, et al. Acute isolated bulbar palsy with anti-GT1a IgG antibody subsequent to Campylobacter jejuni enteritis. J Neurol Sci 2002;205:83-4. (Pubitemid 36158998)
35. Jindal G, Parmar VR, Gupta VK. Isolated ptosis as acute ophthalmoplegia without ataxia, positive for anti-GQ1b immunoglobulin G. Pediatr Neurol 2009;41:451-2.
36. Ropper AH. Unusual clinical variants and signs in Guillain-Barré syndrome. Arch Neurol 1986;43:1150-2. (Pubitemid 17174443)
37. Nagashima T, Koga M, Odaka M, et al. Continuous spectrum of pharyngeal-cervical-brachial variant of Guillain-Barré syndrome. Arch Neurol 2007;64:1519-23. (Pubitemid 47572676)
38. Kimoto K, Koga M, Odaka M, et al. Relationship of bacterial strains to clinical syndromes of Campylobacter-associated neuropathies. Neurology 2006;67:1837-43. (Pubitemid 44900763)
39. Chida K, Nomura H, Konno H, et al. Recurrent Miller Fisher syndrome: clinical and laboratory features and HLA antigens. J Neurol Sci 1999;165:139-43. (Pubitemid 29329513)
40. Hamaguchi T, Yamaguchi K, Komai K, et al. Recurrent anti-GQ1b IgG antibody syndrome showing different phenotypes in different periods. J Neurol Neurosurg Psychiatry 2003;74:1350. (Pubitemid 37152280)
41. Orr CF, Storey CE. Recurrent Miller-Fisher [sic] syndrome. J Clin Neurosci 2004;11:307-9.
42. Willison HJ, Veitch J, Paterson G, et al. Miller Fisher syndrome is associated with serum antibodies to GQ1b ganglioside. J Neurol Neurosurg Psychiatry 1993;56:204-6. (Pubitemid 23075418)
43. Liu JX, Willison HJ, Pedrosa-Domellof F. Immunolocalization of GQ1b and related gangliosides in human extraocular neuromuscular junctions and muscle spindles. Invest Ophthalmol Vis Sci 2009;50:3226-32.
44. Koga M, Yoshino H, Morimatsu M, et al. Anti-GT1a IgG in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 2002;72:767-71.
45. Ropper AH, Shahani B. Proposed mechanism of ataxia in Fisher's syndrome. Arch Neurol 1983;40:537-8. (Pubitemid 13046788)
46. Kuwabara S, Asahina M, Nakajima M, et al. Special sensory ataxia in Miller Fisher syndrome detected by postural body sway analysis. Ann Neurol 1999;45:533-6. (Pubitemid 29165824)
47. Kornberg AJ, Pestronk A, Blume GM, et al. Selective staining of the cerebellar molecular layer by serum IgG in Miller-Fisher [sic] and related syndromes. Neurology 1996;47:1317-20. (Pubitemid 26374906)
48. Koga M, Gilbert M, Li J, et al. Antecedent infections in Fisher syndrome: a common pathogenesis of molecular mimicry. Neurology 2005;64:1605-11. (Pubitemid 40617699)
49. Yuki N, Susuki K, Koga M, et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barré syndrome. Proc Natl Acad Sci U S A 2004;101:11404-9. (Pubitemid 39038359)
50. Houliston RS, Koga M, Li J, et al. A Haemophilus influenzae strain associated with Fisher syndrome expresses a novel disialylated ganglioside mimic. Biochemistry 2007;46:8164-71. (Pubitemid 47051652)
51. Godschalk PCR, Heikema AP, Gilbert M, et al. The crucial role of Campylobacter jejuni genes in anti-ganglioside antibody induction in Guillain-Barré syndrome. J Clin Invest 2004;114:1659-65. (Pubitemid 40385557)
52. Gilbert M, Karwaski MF, Bernatchez S, et al. The genetic bases for the variation in the lipo-oligosaccharide of the mucosal pathogen, Campylobacter jejuni. Biosynthesis of sialylated ganglioside mimics in the core oligosaccharide. J Biol Chem 2002;277:327-37. (Pubitemid 34952062)
53. Koga M, Gilbert M, Takahashi M, et al. Comprehensive analysis of bacterial risk factors for the development of Guillain-Barré syndrome after Campylobacter jejuni enteritis. J Infect Dis 2006;193:547-55. (Pubitemid 43202746)
54. Koga M, Takahashi M, Masuda M, et al. Campylobacter gene polymorphism as a determinant of clinical features of Guillain-Barré syndrome. Neurology 2005;65:1376-81. (Pubitemid 41552764)
55. Yuki N, Hartung HP. Guillain-Barré syndrome. N Engl J Med 2012;366:2294-304.
56. Funakoshi K, Kuwabara S, Odaka M, et al. Clinical predictors of mechanical ventilation in Fisher/Guillain-Barré overlap syndrome. J Neurol Neurosurg Psychiatry 2009;80:60-4.
57. Fross RD, Daube JR. Neuropathy in the Miller Fisher syndrome: clinical and electrophysiologic findings. Neurology 1987;37:1493-8. (Pubitemid 17132330)
58. Jamal GA, Ballantyne JP. The localization of the lesion in patients with acute ophthalmoplegia, ataxia and areflexia (Miller Fisher syndrome). A serial multimodal neurophysiological study. Brain 1988;111:95-114.
59. Kuwabara S, Ogawara K, Misawa S, et al. Does Campylobacter jejuni infection elicit "demyelinating" Guillain-Barré syndrome? Neurology 2004;63:529-33. (Pubitemid 39031386)
60. Dehaene I, Martin JJ, Geens K, et al. Guillain-Barré syndrome with ophthalmoplegia: clinicopathologic study of the central and peripheral nervous systems, including the oculomotor nerves. Neurology 1986;36:851-4. (Pubitemid 16056231)
61. Uncini A, Manzoli C, Notturno F, et al. Pitfalls in electrodiagnosis of Guillain-Barré syndrome subtypes. J Neurol Neurosurg Psychiatry 2010;81:1157-63.
62. Shahrizaila N, Goh KJ, Kokubun N, et al. Serial nerve conduction studies provide insight into the pathophysiology of Guillain-Barré and Fisher syndromes. J Neurol Sci 2011;309:26-30.
63. Umapathi T, Tan EY, Kokubun N, et al. Non-demyelinating, reversible conduction failure in Fisher syndrome and related disorder. J Neurol Neurosurg Psychiatry 2012;83:941-8.
64. Susuki K, Rasband MN, Tohyama K, et al. Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J Neurosci 2007;27:3956-67. (Pubitemid 46597169)
65. Griffin JW, Li CY, Macko C, et al. Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barré syndrome. J Neurocytol 1996;25:33-51.
66. Faraci FM, Choi J, Baumbach GL, et al. Microcirculation of the area postrema. Permeability and vascular responses. Circ Res 1989;65:417-25. (Pubitemid 19194628)
67. van Breemen VL, Clemente CD. Silver deposition in the central nervous system and the hematoencephalic barrier studied with the electron microscope. J Biophys Biochem Cytol 1955;1:161-6.
68. Overell JR, Hsieh ST, Odaka M, et al. Treatment for Fisher syndrome, Bickerstaff's brainstem encephalitis and related disorders. Cochrane Database Syst Rev 2007; (1): CD004761.
69. Mori M, Kuwabara S, Fukutake T, et al. Intravenous immunoglobulin therapy for Miller Fisher syndrome. Neurology 2007;68:1144-6. (Pubitemid 46559850)
70. Hughes RAC, Swan AV, Raphael JC, et al. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain 2007;130:2245-57. (Pubitemid 47327619)
71. Roos RP, Soliven B, Goldenberg F, et al. An elderly patient with Bickerstaff brainstem encephalitis and transient episodes of brainstem dysfunction. Arch Neurol 2008;65:821-4. (Pubitemid 351831463)
72. Hughes RAC, Swan AV, van Doorn PA. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev 2010; (2): CD001446.
73. van Koningsveld R, Schmitz PI, van der Meché FGA, et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet 2004;363:192-6. (Pubitemid 38114716)